Clinical Trial Update: IRE Combined With the Dual-Function Antibody PD-1/CTLA-4 for the Treatment of LAPC Following Failure of First-Line AG Therapy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial is evaluating irreversible electroporation (IRE) combined with a PD-1/CTLA-4 dual-function antibody for locally advanced pancreatic ade…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Pancreatic Adenocarcinoma

Drugs mentioned

• PD-1/CTLA-4 dual-function antibody (PD-1/CTLA-4 dual-function antibody)

Snippet

Sponsor: Ruijin Hospital | Conditions: Pancreatic Adenocarcinoma Locally Advanced | Phase 2 | Status: RECRUITING